518 related articles for article (PubMed ID: 30306859)
21. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
[TBL] [Abstract][Full Text] [Related]
22. Real-world use of PCSK9 inhibitors: A single-center experience.
Sarsam S; Berry A; Degheim G; Singh R; Zughaib M
J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628
[TBL] [Abstract][Full Text] [Related]
23. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
24. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment.
Lang W; Frishman WH
Cardiol Rev; 2019; 27(4):211-217. PubMed ID: 31008773
[TBL] [Abstract][Full Text] [Related]
25. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
26. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence].
Norata GD
G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170
[TBL] [Abstract][Full Text] [Related]
27. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
28. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
29. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
[TBL] [Abstract][Full Text] [Related]
30. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
[TBL] [Abstract][Full Text] [Related]
31. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Rached F; Santos RD
Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
[TBL] [Abstract][Full Text] [Related]
32. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
33. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
Češka R; Táborský M; Vrablík M
Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
[TBL] [Abstract][Full Text] [Related]
34. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.
Page MM; Watts GF
Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511
[TBL] [Abstract][Full Text] [Related]
35. Bococizumab for the treatment of hypercholesterolaemia.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Expert Opin Biol Ther; 2017 Feb; 17(2):237-243. PubMed ID: 28060539
[TBL] [Abstract][Full Text] [Related]
36. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
37. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
38. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
39. Novel Therapeutic Targets for Managing Dyslipidemia.
Sathiyakumar V; Kapoor K; Jones SR; Banach M; Martin SS; Toth PP
Trends Pharmacol Sci; 2018 Aug; 39(8):733-747. PubMed ID: 29970260
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
Tsouka AN; Tellis CC; Tselepis AD
Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
